RealRate Inc., 2040 Martin Ave., Santa Clara, CA 95050

RealRate

July 10, 2026

To the CEO
Praxis Precision
Medicines Inc
99 HIGH STREET, 30TH FLOOR
BOSTON, MA 02110
USA

Praxis Precision Medicines Inc TOP Rated in the US Pharmaceutical Ranking

Dear Sir or Madam,

at RealRate we have just published the 2026 US Pharmaceutical ranking. I am happy to inform you that Praxis Precision Medicines Inc has been TOP Rated at rank 11 out of 178.

Overall, 178 US companies were analyzed with respect to their financial strength. The complete rating is published at https://www.realrate.ai/rankings. Your individual rating report, showing your strengths compared to your competitors is attached.

TOP RATED 2026 RealRate

PRAXIS

RealRate is an international rating agency based in Santa Clara and Berlin. We use artificial intelligence to create fair and explainable company ratings. Customers highly appreciate the RealRate rating seal: only the strongest companies are able to offer highly attractive and innovative products with top customer services. Billion dollar companies rely on our rating and build trust with their customers.

You too can acquire the RealRate seal and advertise with it. We only reach out to the top-rated companies, like yours and only those may subscribe for our seal. Save a lot of money and effort compared to traditional rating agencies: get a RealRate seal for just $9,900. Simply sign the attached order form and send it back via email.

Please feel free to book a short video call with me: https://calendly.com/holger-bartel

Sincerely,

Dr. Holger Bartel, CEO

holger.bartel@realrate.ai • www.realrate.ai • +49 160 957 90 844

RealRate Seal Subscription

RealRate Inc.
2040 Martin Ave., Santa Clara, California 95050, USA
Via email to: holger.bartel@realrate.ai

We subscribe to the Pharmaceutical RealRate rating for Praxis Precision Medicines Inc. The subscription comprises the annual rating update. The invoice will be sent annually, provided that a TOP rating is achieved again. The subscription can be cancelled by written letter, effective for the following year.

RealRate provides the rating seal as a scalable vector graphic. It can be used without any restrictions by Praxis Precision Medicines Inc (Customer) for all promotional purposes, i.e. in product brochures, presentations, websites and broadcasting.

Item	**2026 US Pharmaceutical RealRate rating seal for Praxis Precision Medicines Inc**
Amount	**USD 9,900**
Order no.	2026-0001689548

Amounts payable by Customer are exclusive of taxes. Customer is responsible for all his taxes and will pay such amounts invoiced by RealRate.

Billing address

Company name		Full name	
Street address		Department	
City		Phone number	
State / provice		Email address	
ZIP code			
Country			

Shipping address

The electronic RealRate rating seal and the invoice will be sent to

Delivery email

Praxis Precision Medicines Inc

Date, location, name

PHARMACEUTICAL 2026

Praxis Precision Medicines Inc
Rank 11 of 178



PHARMACEUTICAL 2026

Praxis Precision Medicines Inc
Rank 11 of 178

The relative strengths and weaknesses of Praxis Precision Medicines Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Praxis Precision Medicines Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 188% points.The greatest weakness of Praxis Precision Medicines Inc is the variable Revenues, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 384%, being 155% points above the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	610,911
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	59,771
Liabilities, Non-Current	0
Other Assets	326,849
Other Compr. Net Income	-91
Other Expenses	0
Other Liabilities	0
Other Net Income	22,930
Other Revenues	0
Property and Equipment	147
Research and Development	267,115
Selling, General and Administrative Expense	59,083

Output Variable	Value in 1000 USD
Assets	937,907
Liabilities	59,771
Expenses	326,198
Revenues	0
Stockholders Equity	878,136
Net Income	-303,268
Comprehensive Net Income	-303,314
BaseVar	673,448
ECR before LimitedLiability	323%
Economic Capital Ratio	384%